The company announced the launch of the new products in the US and Europe as part of a product portfolio it has named Panther Scalable Solutions.
Within diagnostics, the firm posted molecular diagnostics revenues of $178.5 million, up 9 percent from $164.3 million in fiscal Q1 2019.
On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.
Revenues of $850.5 million beat the company's prior revenue guidance, as well as the consensus Wall Street estimate.
News items for the in vitro diagnostics industry for the week of Dec. 30, 2019
The investment bank gave PerkinElmer an Outperform rating with a $114 stock price target and Hologic an In Line rating with a $55 stock price target.
News items from the in vitro diagnostics industry for the week of Nov. 18, 2019.
The firm's diagnostics revenues also grew 6 percent year over year with molecular diagnostics revenues up 9 percent.
New resistance tests for Mycoplasma genitalium and gonorrhea could help stave off superbugs, but guidelines and economic factors may hinder adoption.
The case, which was originally being fought between Enzo and Hologic, was decided in favor of Becton Dickinson, Hologic's co-plaintiff.